Buch Ashesh N, Xue Zhenyi, Gevorkian Natalie, Torguson Rebecca, Fournadjieva Jana, Deible Regina, Satler Lowell F, Kent Kenneth M, Pichard Augusto D, Waksman Ron
Washington Hospital Center, Washington, DC, USA.
Am J Cardiol. 2006 Sep 15;98(6):722-4. doi: 10.1016/j.amjcard.2006.03.058. Epub 2006 Jul 21.
Drug-eluting stents (DESs) decrease the need for repeat revascularization in native coronary arteries and vein grafts. This study examined the safety and efficacy of DESs for the treatment of lesions in the internal mammary artery (IMA) conduits and compared the outcomes with those from bare metal stents (BMSs). Records of 69 consecutive patients who underwent stenting of the IMA from 2001 to 2004 were reviewed and analyzed. Of these, 30 patients were treated with DESs (sirolimus- or paclitaxel-eluting stents) and 39 patients with BMSs. In-hospital and 6-month clinical outcomes were recorded and compared. Baseline characteristics were comparable between the 2 groups. Lesion location and characteristics were also similar, except for a trend toward longer stent lengths in the DES group (DES 20.2 +/- 7.7 mm vs BMS 14.8 +/- 3.5 mm, p = 0.255). There was no late thrombosis in either group. There were no significant differences in in-hospital and 1- and 6-month outcomes between the 2 groups, including target lesion revascularization with DESs (DESs 3.33% vs BMSs 10%, p = 0.38). In conclusion, DES implantation into IMAs appears safe and is associated with low rates of recurrences. These results may support expansion of use of DESs for the management of IMA stenotic lesions.
药物洗脱支架（DESs）减少了自体冠状动脉和静脉移植物再次血管重建的需求。本研究探讨了DESs治疗乳内动脉（IMA）血管病变的安全性和有效性，并将结果与裸金属支架（BMSs）进行比较。回顾并分析了2001年至2004年连续69例行IMA支架置入术患者的记录。其中，30例患者接受DESs（西罗莫司或紫杉醇洗脱支架）治疗，39例患者接受BMSs治疗。记录并比较住院期间和6个月时的临床结果。两组患者的基线特征具有可比性。病变部位和特征也相似，不过DES组的支架长度有更长的趋势（DES组为20.2±7.7mm，BMS组为14.8±3.5mm，p = 0.255）。两组均未发生晚期血栓形成。两组在住院期间、1个月和6个月时的结果无显著差异，包括DESs组的靶病变血管重建（DES组为3.33%，BMS组为10%，p = 0.38）。总之，将DESs植入IMA似乎是安全的，且复发率较低。这些结果可能支持扩大DESs在IMA狭窄病变管理中的应用。
